4-(4-Bromophenyl)-thiazol-2-amine derivatives: synthesis, biological activity and molecular docking study with ADME profile.
Deepika SharmaSanjiv KumarBalasubramanian NarasimhanKalavathy RamasamySiong Meng LimSyed Adnan Ali ShahVasudevan ManiPublished in: BMC chemistry (2019)
In order to overcome the challenges of microbial resistance as well as to improve the effectiveness and selectivity of chemotherapeutic agents against cancer, a novel series of 4-(4-bromophenyl)-thiazol-2-amine derivatives was synthesized and its molecular structures were confirmed by physicochemical and spectral characteristics. The synthesized compounds were further evaluated for their in vitro antimicrobial activity using turbidimetric method and anticancer activity against oestrogen receptor positive human breast adenocarcinoma cancer cell line (MCF7) by Sulforhodamine B (SRB) assay. The antimicrobial activity results revealed that compound p2, p3, p4 and p6 exhibited promising antimicrobial activity that are comparable to standard norfloxacin (antibacterial) and fluconazole (antifungal). Anticancer screening results demonstrated that compound p2 was found to be the most active one against cancer cell line when compared to the rest of the compounds and comparable to the standard drug (5-fluorouracil). The molecular docking study demonstrated that compounds, p2, p3, p4 and p6 displayed good docking score within binding pocket of the selected PDB ID (1JIJ, 4WMZ and 3ERT) and showed promising ADME properties.
Keyphrases
- molecular docking
- molecular dynamics simulations
- papillary thyroid
- squamous cell
- candida albicans
- randomized controlled trial
- systematic review
- squamous cell carcinoma
- endothelial cells
- computed tomography
- lymph node metastasis
- microbial community
- high resolution
- magnetic resonance imaging
- radiation therapy
- young adults
- mass spectrometry
- transcription factor
- induced pluripotent stem cells
- small molecule
- childhood cancer
- rectal cancer
- single molecule
- contrast enhanced
- electronic health record
- adverse drug